Free Trial

GeneDx Q3 2023 Earnings Report

GeneDx logo
$92.20 -2.14 (-2.27%)
As of 04:00 PM Eastern

GeneDx EPS Results

Actual EPS
-$0.82
Consensus EPS
-$1.18
Beat/Miss
Beat by +$0.36
One Year Ago EPS
N/A

GeneDx Revenue Results

Actual Revenue
$53.30 million
Expected Revenue
$53.80 million
Beat/Miss
Missed by -$500.00 thousand
YoY Revenue Growth
N/A

GeneDx Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Remove Ads

GeneDx Earnings Headlines

GeneDx management to meet virtually with Craig-Hallum
Elon Warns: Exec Order 14024 Targets Dollar
Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.
BTIG Sticks to Its Buy Rating for GeneDx Holdings (WGS)
See More GeneDx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GeneDx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GeneDx and other key companies, straight to your email.

About GeneDx

GeneDx (NASDAQ:WGS), through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

View GeneDx Profile

More Earnings Resources from MarketBeat